oral semaglutide news demonstrates a 14% reduction in risk of major adverse cardiovascular events DEVELOPING: A new pill for

Journal of Virology, 82 (18), 92889292

10.1128/AAC.00377-16 Antimicrob

C.BrewB

GLP-1 receptor agonists should be considered in patients with type II diabetes and high ASCVD risk OR patients without diabetes who are overweight/obese and have a history of cardiovascular disease

This combination may interact with chemotherapy medicines (like doxorubicin and cisplatin), aluminum-containing antacids (like maalox), estrogen-containing medications (like estradiol), protease inhibitors (like indinavir), statins (like atorvastatin) and anticoagulants (like warfarin)

Contact Keith Law Group for a free consultation and more information on Ozempic Lawsuit claims